drugset / Trial / NCT05798026
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 (dose escalation) of this study will evaluate: The safety and tolerability of EU103 treatment are evaluated for patients with advanced or metastatic solid tumors who have failed standard therapy to determine the maximum tolerated dose and recommended Phase 2 dose. And preliminary efficacy (tumor response), The pharmacokinetic characteristics are evaluated, and changes are investigated.
Timeline
- Start
- 2023-08-08
- Primary completion
- 2025-04-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EU103 | Unknown | 1 mg/kg | Intravenous |
| Subject | EU103 | Unknown | 3 mg/kg | Intravenous |
| Subject | EU103 | Unknown | 6 mg/kg | Intravenous |
| Subject | EU103 | Unknown | 12 mg/kg | Intravenous |
| Subject | EU103 | Unknown | 24 mg/kg | Intravenous |